Reactogenicity, Safety and Immunological Efficacy of the Live, Pentavalent Rotavirus Vaccine in Childhood Immunization
Status:
Completed
Trial end date:
2019-10-25
Target enrollment:
Participant gender:
Summary
The first multicenter prospective, randomized, double-blind, placebo-controlled clinical
trial of the pentavalent live vaccine for RVI prevention was conducted in Russia among
healthy infants aged 2 months at the time of the first vaccination.